17 November, 2025 - LSX Investival in London

Today our CEO Luigi Aurisicchio presented NeoMatrix biotech opportunity to a platea of investors at LSX Investival in London.

We are IMPD-ready and have planned our first clinical study in NSCLC early next year.

If you want to join our journey towards personalized cancer vaccines, contact us!

17 November, 2025 - LSX Investival in London

Seal of Excellence - EU Quality Label

Policy

Contact